Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 16;11(3):670.
doi: 10.3390/vaccines11030670.

BMI-Associated Anti-Apolipoprotein A-1 Positivity in Healthy Adults after mRNA-Vaccination against COVID-19

Roman Máčalík  1 , Marek Petráš  1 , Alexander M Čelko  1 , Petr Chmátal  2 , Jakub Tlapák  2 , Pavel Dlouhý  1 , Jana Malinová  3 , Ivana Králová Lesná  4   5
Affiliations

BMI-Associated Anti-Apolipoprotein A-1 Positivity in Healthy Adults after mRNA-Vaccination against COVID-19

Roman Máčalík et al. Vaccines (Basel). .

Abstract

Elevated anti-apolipoprotein A-1 (AAA1) antibody levels associated with cardiovascular risk have been observed in previously SARS-CoV-2-infected or COVID-19-vaccinated individuals. Since patient safety is generally a priority in vaccination, we sought to investigate AAA1 antibody levels in healthy adults after mRNA vaccination. We conducted a prospective cohort study in healthy adult volunteers recruited from military workers of the Transport Air Base in Prague who had received two doses of mRNA vaccines. Anti-apolipoprotein A-1 antibody levels were determined using ELISA from serum samples obtained at three and four time points after the first and second vaccine doses, respectively, within almost 17 weeks of follow-up. The transient AAA1 positivity rate achieved 24.1% (95% confidence interval CI: 15.4-34.7%), i.e., 20 out of 83 participants had at least one positive post-vaccination sample, with a repeat positivity confirmed in only 5 of them. This rate was associated with a BMI > 26 kg/m2, as documented by an adjusted odds ratio of 6.79 (95% CI: 1.53-30.01). In addition, the highest positivity rate of 46.7% (21.3-73.4%) was observed in obese subjects with >30 kg/m2. Since the incidence rate of AAA1 positivity remained unchanged after the first and second vaccine doses, any relationship between AAA1 positivity and mRNA vaccination was inconclusive. The present study showed a transient AAA1 positivity rate associated with overweight or obesity without a proven association with mRNA vaccination.

Keywords: BMI; anti-apolipoprotein A-1; autoantibody; mRNA vaccination; obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; and in the decision to publish the results.

Figures

Figure 1
Figure 1
Flowchart of the study design (SD: standard deviation).
Figure 2
Figure 2
Proportions of local and systemic adverse events (AEs) in subjects with and without AAA1 positivity.
Figure 3
Figure 3
Development of AAA1 levels, including the interquartile range, during follow-up ((A)—subjects with BMI ≤ 26 kg/m2, (B)—subjects with BMI > 26 kg/m2). * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
See this image and copyright information in PMC

References

    1. Munro A.P.S., Janani L., Cornelius V., Aley P.K., Babbage G., Baxter D., Bula M., Cathie K., Chatterjee K., Dodd K., et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 NCoV-19 or BNT162b2 in the UK (CoV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258–2276. doi: 10.1016/S0140-6736(21)02717-3. - DOI - PMC - PubMed
    1. Stuart A.S.V., Shaw R.H., Liu X., Greenland M., Aley P.K., Andrews N.J., Cameron J.C., Charlton S., Clutterbuck E.A., Collins A.M., et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating MRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-CoV2): A single-blind, randomised, phase 2, non-inferiority trial. Lancet. 2022;399:36–49. doi: 10.1016/S0140-6736(21)02718-5. - DOI - PMC - PubMed
    1. Adjobimey T., Meyer J., Sollberg L., Bawolt M., Berens C., Kovačević P., Trudić A., Parcina M., Hoerauf A. Comparison of IgA, IgG, and neutralizing antibody responses following immunization with moderna, biontech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 vaccines. Front. Immunol. 2022;13:917905. doi: 10.3389/fimmu.2022.917905. - DOI - PMC - PubMed
    1. Petráš M., Lesná I.K., Dáňová J., Čelko A.M. Can vaccination trigger autoimmune disorders? A meta-analysis. Vaccines. 2021;9:821. doi: 10.3390/vaccines9080821. - DOI - PMC - PubMed
    1. Lai Y.-H., Chen H.-Y., Chiu H.-H., Kang Y.-N., Wong S.-B. Peripheral nervous system adverse events after the administration of MRNA vaccines: A systematic review and meta-analysis of large-scale studies. Vaccines. 2022;10:2174. doi: 10.3390/vaccines10122174. - DOI - PMC - PubMed

LinkOut - more resources